Patenting of a Drug Under IPR.

This particular blog discusses how a drug patent may be secured under Indian patent law. In this context, Novartis v. Union of India, a significant Supreme Court decision, has been discussed.

To fully inform the reader on the process of obtaining a drug patent, the various aspects of getting a drug patent have been discussed in this blog.

The many aspects of obtaining a drug patent that is described in this blog include:

The landmark decision in Novartis v. Union of India covers the requirements to patent medication in India and defines the notion of the patent in India.

The conclusion of this blog mentions and explains my results with regard to obtaining a drug patent in India as well as with regard to this important ruling.

Introduction to a Patent

A patent is a legal privilege given to a certain person in relation to his invention, allowing him to prevent others from using, selling, manufacturing, or importing the invention without his or her previous consent.

Consequently, we may conclude that the patent concept is very beneficial to inventors since without it, their ideas could be readily stolen and used by others to their detriment as competitors.

Criteria of Patentability in India

The following requirements for obtaining a patent in India must be met by the inventor's invention:

The term "new" refers to an invention that has not previously been used or published anywhere in the world as of the date the application for the aforementioned patent was filed.

The innovation must include an inventive step; more specifically, one of its features must represent a technical improvement over existing knowledge, have economic value, or both.

The proposed invention must be capable of being used in an industry and should have industrial application capability.

It must not fall under the classification of inventions that are not eligible for patent protection in the relevant country.

A Landmark case law on the patentability of a drug in India is that of-

Novartis v. Union of India-

It is a significant decision on Indian IPR laws. It concerns the denial of a drug patent application that lacked both "invention" and "superior effectiveness."

Facts: In this instance, the Novartis business registered a patent application for the medicine Gleevec.

In order to cover the medicament under the definition of "innovation" as stated in Section 3 of the Patent Act of 1970, the business filed this patent application.

Judgment by the Supreme Court: Following a seven-year legal struggle, the Supreme Court denied Novartis' plea, and the top court cited two key justifications:

1. The court ruled that the Patents Act of 1970 does not consider the discovery of an already-existing medicament to constitute the creation of a new drug.

2. The Patent Act of 1970 stipulates that in addition to proving the traditional steps of novelty, inventive step, and application, a new test is taken into account for claims that cover incremental changes to an existing drug. The Gleevec drug failed to prove this test in this case, according to the ruling of the supreme court.

Therefore, based on this body of case law, it is abundantly clear that in order for a drug to be patentable, it must also pass the tests of novelty, inventive step, and application. Additionally, where a claim pertains to minor adjustments to an already-approved drug, the test of improved therapeutic efficacy also plays a significant role.

CONCLUSION

The topic of obtaining a drug patent in India is covered in length in this blog with the aid of a significant ruling on the subject, Novartis v. Union of India. What is the definition of a patent in India? This blog post also addresses the historic Novartis v. Union of India ruling, which outlines the requirements for a medication to be granted an Indian patent.

As all the many components of obtaining a drug patent in India have been covered in-depth in this article, it will be easier for readers to assess the topic.